Urologic Procedures Uncommon in End-Stage PCa Patients

Share this article:

Only a minority of end-stage prostate cancer (PCa) patients undergo urologic procedures during their final three years of life, according to the first population-based study of its kind.

David F. Jarrard, MD, of the University of Wisconsin School of Medicine in Madison, and colleagues used the Marshfield Epidemiological Study Area (MESA) database and tumor registry to compare end-of-life interventions in men who died from PCar between 1991 and 2009. Of 280 men dying from PCa, 52 (19%) required 153 urological procedures during the last three years of life, the researchers reported online ahead of print in BJU International. The frequency of procedures increased the closer patients were to death. The most common procedures involved placement of a nephrostomy tube (56%) or Foley catheter (24%) and transurethral resection of the prostate (10%).

A history of surgery or radiation did not influence the overall risk for urologic intervention, and clinicopathologic features did not predict the need for an end-of-life urological procedure, according to the investigators.

The study incorporated both hospital- and office-based procedures.

Share this article:
You must be a registered member of RUN to post a comment.

More in Prostate Cancer

Prostate Biopsy Complication Rates Increasing

Prostate Biopsy Complication Rates Increasing

Urologic complications requiring hospital admission grew from 3.6% in 2000 to 3.9% in 2008, largely because of infections.

Good Prostate Cancer (PCa) Outcomes Possible Despite Salvage Radiation Failure

Good Prostate Cancer (PCa) Outcomes Possible Despite Salvage ...

Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.

Early Adjuvant Radiotherapy Benefits Selected Prostate Cancer Patients

Early Adjuvant Radiotherapy Benefits Selected Prostate Cancer Patients ...

Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.